Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20295
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKosmas, I. P.en
dc.contributor.authorZikopoulos, K.en
dc.contributor.authorGeorgiou, I.en
dc.contributor.authorParaskevaidis, E.en
dc.contributor.authorBlockeel, C.en
dc.contributor.authorTournaye, H.en
dc.contributor.authorVan Der Elst, J.en
dc.contributor.authorDevroey, P.en
dc.date.accessioned2015-11-24T19:06:05Z-
dc.date.available2015-11-24T19:06:05Z-
dc.identifier.issn1472-6491-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20295-
dc.rightsDefault Licence-
dc.subjectChorionic Gonadotropin/*administration & dosage/therapeutic useen
dc.subjectCost-Benefit Analysisen
dc.subjectEstradiol/administration & dosage/therapeutic useen
dc.subjectFemaleen
dc.subject*Fertilization in Vitro/economicsen
dc.subjectFollicle Stimulating Hormone/administration & dosage/therapeutic useen
dc.subjectHumansen
dc.subjectOvarian Hyperstimulation Syndrome/prevention & controlen
dc.subjectPregnancyen
dc.subject*Pregnancy Rateen
dc.subjectProgesterone/administration & dosage/therapeutic useen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRetrospective Studiesen
dc.titleLow-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20021711-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractHuman chorionic gonadotrophin (HCG) may substitute FSH to complete follicular growth in IVF cycles. This may be useful in the prevention of ovarian hyperstimulation syndrome. Relevant studies were identified on Medline. To evaluate outcomes, a meta-analysis of low-dose HCG-supplemented IVF cycles versus non-supplemented ones was performed with data from 435 patients undergoing IVF who were administered low-dose HCG in various agonist and antagonist protocols and from 597 conservatively treated patients who served, as control subjects. Using these published data, a decision analysis evaluated four different management strategies. Effectiveness and economic outcomes were assessed by FSH consumption, clinical pregnancy and incremental cost-effectiveness ratios. Clinical pregnancy and ovarian hyperstimulation were the main outcome measures. Nine trials published in 2002-2007 were included. From the prospective studies, in the gonadotrophin-releasing hormone antagonist group, a trend for significance in clinical pregnancy rate was evident (odds ratio [OR], 1.54; 95% confidence interval [CI], 0.98-2.42). Ovarian hyperstimulation was less significant in the antagonist low-dose HCG protocol compared with the non-supplemented agonist protocol (OR 0.30; 95% CI 0.09-0.96). Less FSH was consumed in the low-dose HCG group but this difference was not statistically significant. Low-dose HCG supplementation may improve pregnancy rates in antagonist protocols. Overall, low-dose HCG-supplemented protocols are a cost-effective strategy.en
heal.journalNameReprod Biomed Onlineen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons